ATRA (Atara Biotherapeutics) Institutional Ownership: 30.97% (As of Jul. 12, 2026)


ATRA Atara Biotherapeutics Inc ATRA
31 GF Score
Price $9.72
GF Value $1.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Institutional Ownership?

Atara Biotherapeutics ATRA -2.59% 31 Institutional Ownership is 30.97% as of Jul. 12, 2026. GuruFocus rates ATRA with a GF Score™ of 31/100 and a GF Value™ of $1.55 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Atara Biotherapeutics's institutional ownership is 30.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Atara Biotherapeutics's Insider Ownership is 42.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Atara Biotherapeutics's Float Percentage Of Total Shares Outstanding is 70.19%.

Atara Biotherapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Institutional Ownership Chart

Atara Biotherapeutics Historical Data

The historical data trend for Atara Biotherapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 6.38 6.61 6.86 7.32 8.59 8.70 8.84 8.85 8.33 8.40
ATRA
31GF Score
Atara Biotherapeutics Inc ATRA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 30.97% mean?
Atara Biotherapeutics (ATRA) has a Institutional Ownership of 30.97% as of Jul. 12, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Institutional Ownership too high?
Atara Biotherapeutics' current Institutional Ownership is 30.97%. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Institutional Ownership compare to ANIX and BMEA?
Atara Biotherapeutics' Institutional Ownership of 30.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Institutional Ownership is 30.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.55, compared to a current price of $9.72 — trading 527.1% above its estimated fair value. The current Institutional Ownership is 30.97%. Atara Biotherapeutics' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Institutional Ownership is 30.97% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $9.72 is trading 527.1% above its estimated GF Value™ of $1.55. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • Institutional Ownership: 30.97%
  • GF Value™: $1.55 vs. price of $9.72 (527.1% above fair value)
  • GF Score™: 31/100 with 6 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for ATRA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.72
Price
$1.55
GF Value